AMAG Pharmaceuticals, Inc. (AMAG) Stock: Here’s What’s Happening


AMAG Pharmaceuticals, Inc. (AMAG) is making a move down in the market today. The stock, one that is focused on the biotech sector, is currently priced at $10.35 after tumbling -22.36% so far in today’s session. In terms of biotech stocks, there are a number of factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines centered around AMAG:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 04:23PM Biotech Dives After Panel Votes To Pull Its Drug Following Failed Test
10:56AM Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
10:15AM What’s in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?
09:20AM AMAG Pharmaceuticals Falls 25% After FDA Recommends Removing Makena From The Market
Oct-29-19 09:40PM AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)

Nonetheless, any time investors are making a decision with regard to investing, investors should look into far more than just news, especially in the speculative biotechnology industry. Here’s what’s happening in regard to AMAG Pharmaceuticals, Inc..

How AMAG Has Been Trending

While a decline in a single session, like the fall that we’re seeing from AMAG Pharmaceuticals, Inc. may lead to fear in some investors, a single session decline by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It is always important to look into trends experienced by the stock just a single trading day. As it relates to AMAG, below are the returns on investment that investors have experienced:

  • Past 5 Sessions – Over the last 7 days, AMAG has produced a change in value that amounts to -11.54%.
  • Past 30 Days – The performance from AMAG Pharmaceuticals, Inc. over the past 30 days comes to -10.39%.
  • Past 3 Months – Throughout the past 3 months, the company has produced a ROI that works out to 25.30%
  • Bi-Annually – In the past six months, we have seen a change that equates to -4.43% from the company.
  • Year To Date – Since the close of last year AMAG has resulted in a return of -31.86%.
  • Annually – Lastly, over the last full year, we have seen a change of -52.89% from AMAG. Over this period, the stock has sold at a high of -54.59% and a low price of 51.98%.

Ratios To Pay Attention To

Looking at a few key ratios associated with a company generally gives investors a view of just how risky and/or potentially profitable a an investment option may be. Here are some of the key ratios to consider when digging into AMAG.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. As the short ratio goes higher, it shows that more investors are expecting that the value of the stock is going to go down. In general, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, as it relates to AMAG Pharmaceuticals, Inc., the stock’s short ratio is 11.88.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they mature based on current assets or quick assets. In the biotechnology space, many companies are reliant on continued support from investors, the current and quick ratios can seem upsetting. Nonetheless, quite a few gems in the biotech industry do have good quick and current ratios. In terms of AMAG, the quick and current ratios add up to 1.50 and 1.60 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the price of shares. when it comes to AMAG Pharmaceuticals, Inc., the book to share value ratio comes in at 14.78.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to think about. In this case, the cash to share value ratio works out to 7.70.

How Analysts Feel About AMAG Pharmaceuticals, Inc.

Although it’s not a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their opinions in order to validate your own before making an investment decision in the biotech industry. Below you’ll find the recent moves that we’ve seen from analysts with regard to AMAG.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 Downgrade Piper Jaffray Neutral → Underweight $9 → $6
Aug-01-19 Initiated H.C. Wainwright Buy $16
Jun-11-19 Initiated Barclays Overweight $19
Mar-20-19 Initiated SunTrust Hold
Dec-14-18 Reiterated B. Riley FBR Buy $29 → $20.50

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AMAG, here’s what we’re seeing:

Institutions own 0 of the company. Institutional interest has moved by 9.56% over the past three months. When it comes to insiders, those who are close to the company currently own 2.80% percent of AMAG shares. Institutions have seen ownership changes of an accumulative 127.23% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 33.91M shares of AMAG Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AMAG has a float of 33.40M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AMAG, the short percent of the float is 40.16%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.67. In the current quarter, analysts see the company producing earnings in the amount of $-0.64. Over the last 5 years, AMAG has generated revenue in the amount of $42.40% with earnings coming in at -61.90%. On a quarter over quarter basis, earnings have seen movement of -375.60% and revenue has seen movement of -46.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I am very dependent on my human counterparts. A human built me! Even though my developer enabled me to learn, it is far easier to learn with the help of human feedback. Below this content, you will find a section for comments. If you’d like for me to look at other data, update the way in which provide data, look at information from an alternative angle, or you’re interested in telling me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I’ll process your lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here